tbuckley/cabot-search huggingface dataset:
Why Is Nonadherence to Cancer Screening Associated With Increased Mortality?
Authors: Deborah Grady, Monica Parks
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy
Authors: Eli Muchtar, Angela Dispenzieri, Nelson Leung, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Wilson I Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Stephen J. Russell, John A. Lust, Yi Lin, Ronald S. Go, Steven Zeldenrust, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar, Morie A. Gertz
Journal: Blood (2018)
Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Jean-Marie Michot, Valérie Camara-clayette, Audrey Detolle, Claude Chahine, Julien Lazarovici, Alina Danu, Jacques Bosq, David Ghez, Peggy Dartigues-Cuillères, Julia Arfi-Rouche, Rastilav Bahleda, Wassila Rahali, Andrea Varga, Capucine Baldini, Lambros Tselikas, Clélia Paume, Helene Lecourt, Sophie Cotteret, Veronique Vergé, Jean-Charles Soria, Christophe Massard, Vincent Ribrag
Journal: Blood (2018)
MUC16 gene up-regulates gene transcripts associated with cisplatin resistance in human ovarian cancer cells
Authors: Dharmarao Thapi, Nestor Rosales, Xun Ma, Siobhan Kehoe, John Diaz, David Spriggs
Journal: Cancer Research (2007)

2327  Serum marker CA125 has been used as a measure of ovarian cancer disease progression and therapeutic response for over two decades. The underlying mechanism for the release of CA125 and which factors trigger the release is poorly understood. The gene that encodes the CA125 glycoprotein, MUC16, has been previously identified and sequenced (Yin, 2001; O’Brien, 2001). MUC16 has a molecular size of 22,000 base pairs and consists of a cytoplasmic domain, a transmembrane region and an external domain of up to 60 tandem repeats. The large molecular weight of this gene has made it difficult to study and track in a cell.  In an attempt to better understand this gene, we have designed individual DNA constructs for the multiple components of the MUC16 gene. Three gene constructs were created which encode for the cytoplasmic domain (CD), the one (1R) and the two (2R) external domain tandem repeats. Individual constructs were fused with Vitality phrGFP II C vector system and were successfully transfected into three CA125 negative ovarian cell lines; SKOV3, A2780 and T80. Stable transfectants were made and enriched by cell sorting for GFP. The transfectants were confirmed by FACS analysis with antibodies to GFP and human OC125 which recognizes only the external domain consisting of tandem repeats. The culture supernatants of these transfectants were tested periodically for CA125 by ELISA. Sensitivity to cisplatin (CDDP) was tested by alamar blue cytotoxicity assays on all the stable transfectants. In vitro invasive potential was examined by the Matrigel invasion assay. RT-PCR Super Arrays for 88 human cancer drug resistance & metabolism genes were performed with cDNA’s from these stable transfectants to examine the regulation of drug resistance genes. Protein profiles for the genes involved were confirmed by western blot analysis. FACS analysis was performed for apoptosis assay using Annexin V and 7AAD staining on all stable transfectants.  The SKOV3 stable transfectants with 1 and 2 repeats had increased CA125 secretion to 4 and 7 units/ml, respectively.SKOV3, A2780 and T80 stable transfectants showed a modest increased resistance to CDDP compared to vector control. In vivo tumor growth specifically with SKOV3 1R-GFP transfected cell line in athymic nude mice showed a marked resistance to CDDP compared to the vector control. Matrigel invasion assay with SKOV3 transfectants demonstrated a more invasive potential than vector only (1R = 36% vs Vector = 15% invasion). Transcripts for 19 drug resistance & metabolism genes were significantly up-regulated 3-23 fold (p
Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)
Authors: Jeffrey I. Zwicker, Benjamin L. Schlechter, Jack Davis Stopa, Howard A. Liebman, Anita Aggarwal, Thomas Caughey, Ken A. Bauer, Nancy Kuemmerle, Ellice Y. Wong, Ted Wun, Marilyn Mclaughlin, Maneka Puligandla, Donna S Neuberg, Bruce Furie, Robert C. Flaumenhaft
Journal: Blood (2018)
Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL).
Authors: Scott F. Huntington, Sunita Nasta, Stephen J. Schuster, Jalpa Doshi, Jakub Svoboda
Journal: Journal of Clinical Oncology (2014)

8549 Background: FDG-PET/CT (PET/CT) is part of standard pre-treatment staging and post-treatment response assessment in patients undergoing first line therapy for DLBCL. While many providers obtain interim PET/CT (I-PET) during the course of therapy, the role of these scans remains unclear. We investigated the clinical utility of interim and end of treatment PET/CT (E-PET) in patients with DLBCL. Methods: All patients with biopsy confirmed DLBCL undergoing first line therapy at our institution between January 1, 2008 and June 1, 2012 were screened for this retrospective study. Patients who received immunochemotherapy and underwent at least one I-PET were included for analysis. Scan results were interpreted as positive or negative based on consensus criteria from the International Harmonization Project. Results from I-PET and E-PET were analyzed and clinical outcomes were recorded. Results: Of 101 patients with DLBCL undergoing first line treatment at our institution, 94 patients underwent at least one I-PET. The median age was 58.5 years (range 20-91), 55% were male, and median follow-up time was 32.2 months. The majority (61%) of patients had at least one negative I-PET and a total of 133 I-PETs and 84 E-PETs were obtained. The positive predictive value (PPV) and negative predictive value (NPV) of I-PET for predicting primary refractory disease were 40.5% (95% CI:25-58%) and 100% (95% CI: 92-100%) respectively. The PPV and NPV of I-PET for predicting primary refractory or relapsed disease were 51.4% (95% CI: 35-68%) and 86.8% (95% CI: 74-94%). Obtaining at least one negative I-PET was strongly associated with improved progression-free survival (PFS) and remained an independent prognostic factor in a bivariate Cox model with revised-IPI (negative I-PET: HR 0.31, p=0.002; R-IPI: HR 2.4, p=0.02). Conclusions: Negative I-PET predicted superior clinical outcomes in our DLBCL patient cohort. All patients with negative I-PET were in remission at end of treatment and E-PET offered little clinical utility in this patient subset. Therefore, I-PET may offer an approach of early prediction of treatment outcome and obviate the need for end of therapy imaging in a majority of patients with DLBCL.
Amit Sengupta: founder and advocate of the People’s Health Movement in India
Authors: Jeetha D’Silva
Journal: BMJ (2019)

In death, as in life, Amit Sengupta was recognised as one of the most vocal advocates of universal access to healthcare and a leader of the People’s Health Movement (PHM), a network of organisations committed to democratising global health governance. As news of his untimely death spread, PHM’s website was inundated with tributes from across the globe.

“Amit was a great defender of the human right to health. His enthusiasm, energy, deep knowledge, and clear thinking were great assets to the health movement. His legacy will remain for generations to come.”

“Amit was a steadfast and determined activist, a pillar of the global people’s movement. You could always count on him to speak up for the oppressed, the marginalised, and the voiceless.”

“Amit Sengupta believed in, represented, and defended the values of the People’s Health Movement and advocated health for all. While he is no longer around, we, as a global community of health advocates, are challenged to fill the void he left, a massive challenge and one that will require both, as he put it, ‘purposeful optimism’ and ingenuity in order to achieve health for all in our lifetime.”

Sengupta was a true champion of the masses. Born in Kolkata in 1958, he studied medicine at Maulana Azad Medical College in Delhi, where he organised and participated in a number of student led agitations. As a young doctor, he used his newly acquired medical skills to help others in times of need. He provided …
Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL)
Authors: Pavan Bachireddy, Nikolaos Barkas, Sachet A Shukla, Samuel Freeman, Liudmila Elagina, Vinhkhang N Nguyen, Kendell Clement, Ignaty Leshchiner, Jennifer R. Brown, Donna S Neuberg, Vincent T. Ho, Robert J. Soiffer, Jerome Ritz, Gad Getz, Edwin P. Alyea, Peter Kharchenko, Catherine J. Wu
Journal: Blood (2018)
SP0042 Recent advances in the treatment of systemic sclerosis
Authors: J.M. Van Laar
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Few rheumatological diseases have seen as many false dawns as systemic sclerosis (SSc) and many drugs once hailed as promising have fallen by the wayside. Clinical trials have been plagued by poor accrual, difficulties with definitions of endpoints, clinical heterogeneity of disease manifestations and variability of disease course, resulting in inconclusive or negative trial results. Clinicians standing in the shadows of no man's land could be forgiven for not seeing the sparks of light around them. Yet our grasp of the pathological pathways operative in SSc, consensus on endpoints and international collaboration have paved the way for clinical trials with novel antibrotic and immunomodulatory drugs (e.g. rociguat, JAK-STATi) that could change the way we treat SSc. For now we will have to stick to old friends such as methotrexate, MMF and cyclophosphamide in early diffuse cutaneous SSc, even though their clinical benefit is modest at best as shown in the ESOS study and expressed in recent guidelines.<sup><sup>1–3</sup></sup> Rituximab is increasingly being used based on observational studies in SSc and its proven potency in rheumatoid arthritis, but requires more robust data. Tocilizumab has shown unexpected benefit on lung function in a phase 2 trial,<sup><sup>4</sup></sup> which if confirmed with phase 3 trial could transform the way we manage SSc-ILD. As of yet, the only proven disease modifyinge therapy in early progressive SSc is autologous hematopoietic stem cell transplantation, shown to be effective in two prospective, controlled randomised clinical trials (ASTIS and SCOT, conducted in Europe and North America respectively)(.<sup><sup>5,6</sup></sup> Only a small group of patients qualify for this however and even fewer have access to centres with the necessary expertise. SSc continues to constitute an area of unmet need, yet progress is being made, albeit slow. <h3>References</h3> [1] Herrick, et al. Ann Rheum Dis2017;76:1207–18. [2] Kowal-Bielecka, et al. Ann Rheum Dis2017;76:1327–39. [3] Denton, et al. Rheumatology2016;55:1906–10. [4] Khanna, et al. Ann Rheum Dis2018;77:212–20. [5] Van Laar, et al. JAMA2014;311:2490–8. [6] Sullivan, et al. N Engl J Med2018;378:35–47. <h3>Disclosure of Interest</h3> J. Van Laar Grant/research support from: Astra Zeneca, Roche-Genentech, MSD, Consultant for: Arthrogen, BMS, Eli Lilly, Pfizer, Roche, Speakers bureau: Janssen
1129 SERPIN-B3 AS A PRO-FIBROGENIC MEDIATOR CONTRIBUTING TO CHRONIC LIVER DISEASE PROGRESSION
Authors: C. Paternostro, C. Busletta, C. Turato, S. Cannito, G. Villano, A. Biasiolo, S. Quarta, E. Novo, M. Pinzani, M. Parola, P. Pontisso
Journal: Journal of Hepatology (2013)
Abstract 14988: Prophylactic Pulmonary Vein Isolation During Isthmus Ablation for Atrial Flutter: Three-Year Outcomes of the PREVENT AF I Study
Authors: Jonathan Steinberg, Alexander Romanov, Sevda Bayramova, Vitaliy Shabanov, Denis Losik, Dmitry Ponomarev, Ilya Stenin, Dmitry Elesin, Igor Mikheenko, Evgeny Pokushalov
Journal: Circulation (2017)

Introduction: The PREVENT AF I study demonstrated that prophylactic pulmonary vein isolation (PVI) in patients with typical atrial flutter (AFL) resulted in substantial reduction of new onset atrial fibrillation (AF) during 1-year follow up as assessed by continuous implantable loop recorder (ILR). Objective: To assess the 3-year outcome in AF prevention by prophylactic PVI in patients with only typical AFL. Methods: Fifty patients with documented AFL were randomized to either cavo-tricuspid isthmus (CTI) ablation alone (n=25) or CTI with concomitant PVI (PVI; n=25). All patients received an ILR with regular follow-up for 3 years following initial ablation. The primary endpoint of the study was the occurrence of any atrial tachyarrhythmia including AF or AFL after ablation with the monthly burden exceeding 0.5% on the ILR. Results: At the end of 3 years, 80% of the patients in CTI only group vs 52% of the patients in PVI+CTI group developed AF/AFl recurrences [hazard ratio (HR) 2.40, 95% confidence interv...
A Status Update on the Association Between Antidepressants and Fractures
Authors: Andrea Iaboni, Donovan T. Maust
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Management of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Proteasome Inhibitor Based Therapy at First Relapse in Routine Clinical Practice in Germany
Authors: H. Tilman Steinmetz, Moushmi Singh, Andrea Lebioda, Aurelien Mantonnier, Leah Fink, Achim Rieth, Florence Suzan, Sebastian Gonzalez-McQuire
Journal: Blood (2018)
Combination therapy with ciprofloxacin and third-generation cephalosporin versus third-generation cephalosporin monotherapy in Escherichia coli meningitis in infants: a multicentre propensity score–matched observational study
Authors: M. Tauzin, N. Ouldali, C. Lévy, S. Béchet, R. Cohen, L. Caeymaex
Journal: Clinical Microbiology and Infection (2018)
IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
Authors: Alexander Starodub, Allyson J. Ocean, Michael J. Guarino, Vincent J. Picozzi, Sajeve Samuel Thomas, Wells A. Messersmith, Manish A. Shah, Linda T. Vahdat, Ellen Chuang, Bruce S. Lin, Serengulam V. Govindan, Pius P Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg
Journal: Journal of Clinical Oncology (2014)

3032 Background: IMMU-132 is an ADC of the internalizing, humanized, anti-Trop-2 antibody, hRS7, conjugated by a pH-sensitive linker, to SN-38, the active metabolite of CPT-11 (mean drug-antibody ratio = 7.6). Trop-2 is a type I transmembrane, calcium-transducing, protein expressed at high density (~1 x 10*5), frequency, and specificity by many human carcinomas, with limited normal tissue expression. Methods: We report the initial Phase I trial of 25 patients (pts) who had failed multiple prior therapies (some including topoisomerase-I/II inhibiting drugs), and the ongoing Phase II extension that focused on pts with colorectal (CRC), small-cell lung (SCLC) and triple-negative breast (TNBC) cancers. Results: Trop-2 is not detected in serum, but was strongly expressed (≥2+) in most archived tumors. In a 3+3 trial design, IMMU-132 was given on days 1 and 8 in repeated 21-day cycles, starting at 8 mg/kg/dose, then 12 and 18 mg/kg before dose-limiting neutropenia. To optimize cumulative treatment with minimal delays, phase II is focusing on 8 and 10 mg/kg (n=22 and 14, respectively). Most common non-hematological toxicities were fatigue (17 ≤G2 ,4 G3), nausea (20 ≤G2), diarrhea (12 ≤G2, 3 G3), alopecia (14), and vomiting (10 ≤G2) ; 2 pts had a rash. Homozygous UGT1A1 *28/*28 was found in 5 pts, 2 of whom had more severe hematological and GI toxicities. Over 80% of 24 assessable pts in Phase I had stable disease or tumor shrinkage (17 SD; 3 PR [CRC, TNBC, SCLC]) as best CT response; median TTP = 18 weeks for all pts, except pancreatic cancer. Of the 36 pts in the Phase II, 14 had their first response assessment by CT: 6 PD, 7 SD; 1 PR (SCLC) by RECIST1.1. Tumor markers (CEA, CA19-9) correlated with responses. No anti-hRS7 or anti-SN-38 antibodies were detected despite dosing over months. The conjugate clears within 7 days, consistent with in vivo animal studies where 50% of the SN-38 is released daily. Conclusions: These results indicate that this novel SN-38-containing ADC is active in metastatic solid cancers, with manageable diarrhea and neutropenia. The Phase II continues, while also accruing in other epithelial tumors. Clinical trial information: NCT01631552.
Guidelines for Reporting of Statistics for Clinical Research in Urology
Authors: Melissa Assel, Daniel Sjoberg, Andrew Elders, Xuemei Wang, Dezheng Huo, Albert Botchway, Kristin Delfino, Yunhua Fan, Zhiguo Zhao, Tatsuki Koyama, Brent Hollenbeck, Rui Qin, Whitney Zahnd, Emily C. Zabor, Michael W. Kattan, Andrew J. Vickers
Journal: European Urology (2018)
The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment
Authors: Yandong Shen, Kyle R Crassini, Michael E O'Dwyer, Michael Francis O'Neill, Richard Christopherson, Stephen P. Mulligan, Oliver Giles Best
Journal: Blood (2018)
The retrospective study for unplanned hospital admission of patients with cancer who visited the emergency department.
Authors: Tae Tanaka, Hidetoshi Hayashi, Masataka Taguri, Soichi Fumita, Yoshio Matsuo
Journal: Journal of Clinical Oncology (2014)

e20703 Background: The purpose was to establish criteria to predict the need for unplanned hospital admission of patients with cancer who visited the Emergency Department (ED). Methods: The patients with cancer who visited the ED of Kishiwada Municipal Hospital from April 1, 2012 to March 31, 2013 were examined. We performed descriptive statistics and logistic regressions. Results: Of 15,716 ED visits, there were 1,244 ED visits (7.9%) of patients with cancer. Emergency hospitalizations were 462 cases (37.1%) and cardiopulmonary arrests on arrival were 12 cases (0.96%). The mean age was 71 years and the majority of patients were male. The most common type of cancer was lung (18.2%), followed by gastric (16.2%), and colorectal (14.5%). Patients with lung cancer or hepatic cell carcinoma, PS 2-4, comorbidity and metastasis were more likely to be admitted than counterparts. On the other hand, no significant difference was observed between the cases with and without emergency hospitalization regarding the cases of chemotherapy within 14 days, within 30 days, or the operation within 30 days. In 450 cases of the patients with metastasis, a significantly higher number of the emergency hospitalization were associated with the factors of age ≥ 76 years, altered mental status, SpO2 < 90%, WBC < 2,000 /μl or WBC > 10,000 /μl, Alb ≤ 2.5 g/dL, BUN ≥ 25 mg/dL, AST ≥ 100 IU/L and CRP ≥ 10 mg/dL. Multiple logistic regression models indicated that the elderly, altered mental status, hypoxia, WBC count abnormality and elevated CRP were independent predictive factors for emergency hospitalization. Conclusions: Our findings suggested that the several factors could predict the emergency hospitalization related to cancer.
Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients &gt; 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)
Authors: Nadia Jaekel, Karolin Hubert, Mathias Hänel, Georg Maschmeyer, Regina Herbst, Susann Schulze, Song-Yau Wang, Christoph Kahl, Maxi Wass, Herbert G. Sayer, Oana Brosteanu, Dietger Niederwieser, Haifa Kathrin Al-Ali
Journal: Blood (2018)